UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether erlotinib will be effective in controlling
cancer that has returned after treatment with salvage surgery and radiation. This study will
also determine what effects, good and/or bad, this drug has on the participants.